We are live on
!
Find out more
EUCRU
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU
Delisted
EUCRU was delisted on the 26th of April, 2023.
23 hedge funds and large institutions have $50.9M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
38% less funds holding
Funds holding: 37 → 23 (-14)
44% less capital invested
Capital invested by funds: $90.4M → $50.9M (-$39.5M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
Holders
23
Holders Change
-14
Holders Change %
-37.84%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
6
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.24M |
| 2 |
HM
HealthCor Management
New York
|
+$3.56M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$216K |
| 4 |
Morgan Stanley
New York
|
+$41.5K |
| 5 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$27.7K |
Top Sellers
| 1 |
BlackRock
New York
|
-$9.86M |
| 2 |
6CM
683 Capital Management
New York
|
-$6.4M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.78M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.2M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.2M |
